Is Aimovig a CGRP-Targeted Therapy?
Yes, Aimovig (erenumab) is definitively a calcitonin gene-related peptide (CGRP)-targeted therapy—specifically, it is a fully human monoclonal antibody that binds to and antagonizes the CGRP receptor. 1
Mechanism of Action
Erenumab-aooe is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to the CGRP receptor and antagonizes CGRP receptor function. 1 Unlike other CGRP-targeted therapies that bind to the CGRP ligand itself (such as fremanezumab, galcanezumab, and eptinezumab), erenumab is the first and only fully human monoclonal antibody designed to target and block the CGRP receptor directly. 2
Classification Among CGRP-Targeted Therapies
The American College of Physicians' 2025 guideline classifies erenumab as a CGRP monoclonal antibody (CGRP-mAb), distinguishing it from CGRP antagonist-gepants (atogepant and rimegepant). 3 This classification reflects the different mechanisms:
- CGRP monoclonal antibodies (erenumab, eptinezumab, fremanezumab, galcanezumab): Large molecule biologics administered by injection 3
- CGRP antagonist-gepants (atogepant, rimegepant): Small molecule oral medications 3
Receptor Specificity
While designed to target the canonical CGRP receptor (comprising the calcitonin receptor-like receptor and receptor activity-modifying protein 1), emerging evidence demonstrates that erenumab can also antagonize the AMY1 receptor with approximately 20-120-fold preference for the CGRP receptor. 4 This broader receptor activity may contribute to its clinical profile, though the primary therapeutic target remains the CGRP receptor. 4
FDA Approval and Indication
Erenumab is FDA-approved as a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. 1 It received initial U.S. approval in 2018 as the first-in-class CGRP receptor antagonist. 1, 5
Clinical Positioning
The 2025 ACP guideline recommends CGRP monoclonal antibodies, including erenumab, as second-line therapy for episodic migraine prevention in patients who do not tolerate or inadequately respond to first-line agents (beta-blockers, valproate, venlafaxine, or amitriptyline). 3 The 2024 VA/DoD guideline provides a "strong for" recommendation for erenumab in both episodic and chronic migraine prevention. 3